<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Renal effects of ACE inhibitors in heart failure</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Renal effects of ACE inhibitors in heart failure</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Renal effects of ACE inhibitors in heart failure</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Wilson S Colucci, MD</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Richard H Sterns, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Stephen S Gottlieb, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">John P Forman, MD, MSc</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jan 23, 2024.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Angiotensin-converting enzyme (ACE) inhibitors are widely used in the treatment of heart failure. These agents decrease the formation of angiotensin II, thereby decreasing both arteriolar and venous resistance. This vasodilator effect causes immediate improvement in the symptoms of heart failure by decreasing left ventricular afterload, thereby increasing cardiac output and decreasing left and right heart filling pressures, which ameliorates pulmonary and systemic venous congestion. Due to their pleiotropic effects on various target organs including the heart, vasculature, and kidneys, ACE inhibitors slow the rate of progressive cardiac dysfunction and produce an approximately 25 percent reduction in cardiovascular mortality at one to three years [<a href="#rid1">1-4</a>]. In addition, the administration of an ACE inhibitor after an acute myocardial infarction can preserve cardiac function (as evidenced by an increased ejection fraction and slowed ventricular enlargement) and improve long-term survival [<a href="#rid5">5</a>].</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/74.html" rel="external">"Angiotensin converting enzyme inhibitors and receptor blockers in acute myocardial infarction: Recommendations for use"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/121086.html" rel="external">"Primary pharmacologic therapy for heart failure with reduced ejection fraction", section on 'Primary components of therapy'</a>.)</p><p></p><p>An ACE inhibitor given with a loop diuretic may have the additional advantage of raising the plasma sodium concentration in patients with heart failure and hyponatremia [<a href="#rid6">6</a>]. This synergism may reflect factors that result in an increase in free water excretion. (See  <a class="medical medical_review" href="/z/d/html/2321.html" rel="external">"Hyponatremia in patients with heart failure"</a>.)</p><p>In addition to a possible elevation in free water excretion, ACE inhibitors have other renal actions in heart failure, including changes in the glomerular filtration rate (GFR), reduced potassium excretion that can lead to hyperkalemia, and variable effects on the natriuretic response to diuretics.</p><p class="headingAnchor" id="H2"><span class="h1">EFFECT ON GLOMERULAR FILTRATION RATE</span><span class="headingEndMark"> — </span>In view of the improvement in cardiac output and in renal blood flow, it might be assumed that ACE inhibitors would also increase the glomerular filtration rate (GFR). However, this expected response occurs in only 10 to 25 percent of patients, while an increase in the plasma creatinine concentration is a more common finding [<a href="#rid7">7-9</a>]. As an example, the Cooperative North Scandinavian <a class="drug drug_general" data-topicid="9405" href="/z/d/drug information/9405.html" rel="external">Enalapril</a> Survival Study (CONSENSUS) trial of patients with severe heart failure noted a mean elevation in the plasma creatinine concentration of 0.1 to 0.2 mg/dL (10 to 20 micromol/L); furthermore, 11 percent of patients had more than a 100 percent rise in the plasma creatinine concentration [<a href="#rid8">8</a>]. This usually modest decline in GFR occurs within the first week; kidney function then tends to be stable unless a complicating factor, such as worsening of cardiac function, is superimposed [<a href="#rid8">8</a>].</p><p>A reduction in GFR in heart failure is most likely to occur in those settings in which maintenance of the GFR is dependent upon high ambient angiotensin II levels [<a href="#rid6">6-10</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Patients on high-dose diuretic therapy in whom there is relative hypovolemia due to excessive diuresis</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients with relative hypotension (mean arterial pressure below 75 mmHg) after therapy, which is usually reflective of a low cardiac output and associated low renal blood flow</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients with a pretreatment plasma sodium concentration below 137 mEq/L, which is a marker for marked neurohumoral activation</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients with significant renovascular disease, a common finding among older adults with heart failure [<a href="#rid10">10</a>]</p><p></p><p>In theory, the plasma renin activity should also identify patients at risk. However, measurement of the plasma renin activity is not a useful clinical test because circulating renin may not reflect the activity of <strong>tissue</strong> renin-angiotensin systems (see  <a class="medical medical_review" href="/z/d/html/3815.html" rel="external">"Renin-angiotensin system inhibition in the treatment of hypertension"</a>). As an example, patients with stable heart failure may have a normal plasma renin activity [<a href="#rid11">11</a>]. However, studies in animals with heart failure have shown that the intrarenal renin-angiotensin system may still be activated in this setting, an appropriate response to the fall in kidney perfusion [<a href="#rid12">12</a>]. Thus, even in patients with a normal plasma renin activity, an ACE inhibitor may lower the GFR by decreasing intrarenal angiotensin II.</p><p>The ACE inhibitor-induced fall in GFR in heart failure is due, at least in part, to a preferential reduction in efferent arteriolar resistance in the glomerulus, which leads to a reduction in intraglomerular pressure, which is the primary driving force for glomerular filtration. The baseline level of glomerular filtration can often be restored by lowering the diuretic dose, thereby decreasing the angiotensin II dependence of glomerular filtration. In addition, use of nonsteroidal antiinflammatory drugs should be avoided, if possible. (See  <a class="medical medical_review" href="/z/d/html/121086.html" rel="external">"Primary pharmacologic therapy for heart failure with reduced ejection fraction", section on 'Worsening renal function'</a>.)</p><p>It has also been suggested that a decline in GFR may be less likely to occur with a short-acting ACE inhibitor such as <a class="drug drug_general" data-topicid="9196" href="/z/d/drug information/9196.html" rel="external">captopril</a> [<a href="#rid13">13</a>]. This observation was based upon a study in which relatively high doses of <a class="drug drug_general" data-topicid="9405" href="/z/d/drug information/9405.html" rel="external">enalapril</a> were used [<a href="#rid13">13</a>]. Initiating therapy with a low dose of enalapril or <a class="drug drug_general" data-topicid="9565" href="/z/d/drug information/9565.html" rel="external">lisinopril</a> (as with 2.5 mg of enalapril) is probably as safe as captopril in most patients [<a href="#rid1">1,6,14</a>].</p><p>Studies in experimental animals suggest that there may be differences in the degree to which individual ACE inhibitors inhibit tissue-converting enzymes in the presence of heart failure. As an example, <a class="drug drug_general" data-topicid="9405" href="/z/d/drug information/9405.html" rel="external">enalapril</a> may be a more potent inhibitor of renin ACE than <a class="drug drug_general" data-topicid="9196" href="/z/d/drug information/9196.html" rel="external">captopril</a>; rather than leading to a reduction in GFR, this change may lead to a moderate increase in sodium excretion, a possible reflection of diminished proximal sodium reabsorption due to removal of the normal stimulatory effect of angiotensin II [<a href="#rid15">15</a>]. The relevance of these findings to humans remains to be proven.</p><p class="headingAnchor" id="H679155627"><span class="h2">Patients who also have chronic kidney disease</span><span class="headingEndMark"> — </span>Due to the potential that ACE inhibitors may lower GFR, they tend to be underused in patients with heart failure who also have chronic kidney disease. However, several studies suggest that the beneficial effects of ACE inhibitors and angiotensin receptor blockers (ARBs) on mortality and heart failure hospitalization extend to patients with chronic kidney disease and impaired kidney function [<a href="#rid16">16</a>].</p><p class="headingAnchor" id="H3"><span class="h2">Approach to changes in glomerular filtration rate</span><span class="headingEndMark"> — </span>The decline in GFR induced by an ACE inhibitor in heart failure can be minimized or prevented by the combination of low initial doses plus a transient decrease in diuretic dosage [<a href="#rid7">7</a>]. The plasma creatinine and potassium concentrations should be measured within the first week since a deleterious change in renal hemodynamics or potassium excretion should occur in this time period [<a href="#rid8">8</a>].</p><p>Our approach to deleterious changes in kidney function after initiation of ACE inhibitor therapy are as follows:</p><p class="bulletIndent1"><span class="glyph">●</span>The ACE inhibitor should be stopped, and specialist advice should be sought, if any of the following occur:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>The serum creatinine increases by more than 100 percent above baseline</p><p class="bulletIndent2"><span class="glyph">•</span>The serum creatinine rises to above 3.5 mg/dL (310 micromol/L)</p><p class="bulletIndent2"><span class="glyph">•</span>The estimated GFR falls to below 20 mL/min/1.73 m<sup>2</sup></p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The dose of the ACE inhibitor should be decreased by one-half, and the creatinine should be repeated in approximately one week, if any of the following occur:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>The serum creatinine increases to a level that is 50 to 100 percent above baseline</p><p class="bulletIndent2"><span class="glyph">•</span>The serum creatinine increases to a level between 3 and 3.5 mg/dL (266 to 310 micromol/L)</p><p class="bulletIndent2"><span class="glyph">•</span>The estimated GFR fall to a level between 20 and 25 mL/min/1.73 m<sup>2</sup></p><p></p><p class="bulletIndent1">If the response to decreasing the dose is not satisfactory, specialist advice should be sought.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>By contrast, the following changes in kidney function are generally considered acceptable:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>An increase in serum creatinine of up to 50 percent above baseline</p><p class="bulletIndent2"><span class="glyph">•</span>An increase in serum creatinine up to 3 mg/dL (266 micromol/L)</p><p class="bulletIndent2"><span class="glyph">•</span>An estimated GFR that falls as low as 25 mL/min/1.73 m<sup>2</sup></p><p></p><p class="headingAnchor" id="H4"><span class="h1">HYPERKALEMIA</span><span class="headingEndMark"> — </span>Patients with underlying kidney function impairment are also at higher risk for the development of hyperkalemia following the administration of an ACE inhibitor [<a href="#rid6">6,17</a>]. Advanced heart failure is associated with decreased sodium and water delivery to the potassium secretory site in the collecting tubules. Maintenance of adequate potassium secretion in these patients is dependent upon increased secretion of aldosterone, a response that may be partially impaired if there is diminished production of angiotensin II (since angiotensin II is the primary mediator of the hypoperfusion-induced increase in aldosterone release). The risk of hyperkalemia is increased with the concomitant administration and/or uptitration of an aldosterone antagonist such as <a class="drug drug_general" data-topicid="9943" href="/z/d/drug information/9943.html" rel="external">spironolactone</a>.</p><p class="headingAnchor" id="H5"><span class="h1">NATRIURETIC RESPONSE TO DIURETICS</span><span class="headingEndMark"> — </span>Although ACE inhibitors commonly decrease the glomerular filtration rate (GFR) due to their differential effects on proximal and distal glomerular arterioles, ACE inhibitors can increase the natriuretic response to diuretics under certain circumstances. As an example, when acutely given in very low doses (eg, 1 mg of <a class="drug drug_general" data-topicid="9196" href="/z/d/drug information/9196.html" rel="external">captopril</a>), the response to a loop diuretic is enhanced. This may be mediated by a decline in proximal sodium reabsorption induced by the reduction in intrarenal angiotensin II [<a href="#rid18">18</a>]. The GFR is stable in this setting, presumably because sufficient angiotensin II is available to sustain efferent arteriolar tone. At higher doses, however, both a fall in systemic blood pressure and, as described above, a decrease in GFR can occur that may attenuate the diuretic response by as much as 50 percent [<a href="#rid18">18,19</a>].</p><p>This interplay between ACE inhibitors and diuretics may be clinically important. One study that evaluated patients chronically treated with <a class="drug drug_general" data-topicid="9196" href="/z/d/drug information/9196.html" rel="external">captopril</a> (given at 12.5 mg three times daily) found that ACE inhibition moderately increased the diuretic response to <a class="drug drug_general" data-topicid="8482" href="/z/d/drug information/8482.html" rel="external">furosemide</a> by approximately 20 percent, despite reductions in blood pressure and GFR [<a href="#rid20">20</a>]. In another study, captopril administration to patients who had been diuretic resistant on therapy with <a class="drug drug_general" data-topicid="8528" href="/z/d/drug information/8528.html" rel="external">hydralazine</a> or <a class="drug drug_general" data-topicid="9707" href="/z/d/drug information/9707.html" rel="external">nitroprusside</a> improved diuretic responsiveness and also improved GFR and renal blood flow [<a href="#rid21">21</a>]. Because ACE inhibitors are relatively selective for renal arteries, the increase in renal blood flow with ACE inhibitors for any given increase in cardiac output is greater than with nonselective vasodilators such as hydralazine or inotropes such as <a class="drug drug_general" data-topicid="9380" href="/z/d/drug information/9380.html" rel="external">dobutamine</a> [<a href="#rid22">22</a>].</p><p class="headingAnchor" id="H27655912"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Effects on kidney function</strong> – Approximately 10 to 25 percent of patients with heart failure have improvement in kidney function after initiation of angiotensin-converting enzyme (ACE) inhibitors, presumably due sequentially to an improvement in cardiac output and increase in renal blood flow. However, a worsening of glomerular filtration rate (GFR) is more common. Worsening of GFR is due, at least in part, to reduction of efferent arteriolar resistance superimposed on relatively low kidney perfusion. A reduction in GFR in heart failure is most likely to occur in the following settings (see <a class="local">'Effect on glomerular filtration rate'</a> above):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Patients on diuretic therapy in whom there is relative hypovolemia</p><p class="bulletIndent2"><span class="glyph">•</span>Patients with relative hypotension (mean arterial pressure below 75 mmHg) after therapy</p><p class="bulletIndent2"><span class="glyph">•</span>Patients with a pretreatment plasma sodium concentration below 137 mEq/L</p><p class="bulletIndent2"><span class="glyph">•</span>Patients with significant renovascular disease</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Monitoring</strong> – This usually modest decline in GFR occurs within the first week; kidney function then tends to be stable unless a complicating factor, such as worsening of cardiac function, is superimposed. Thus, the plasma creatinine and potassium concentrations should be measured within the first week since a deleterious change in renal hemodynamics or potassium excretion should occur in this time period. (See <a class="local">'Approach to changes in glomerular filtration rate'</a> above.)</p><p></p><p class="bulletIndent1">Patients with underlying kidney function impairment and those taking aldosterone antagonists are at higher risk for the development of hyperkalemia following the administration of an ACE inhibitor. (See <a class="local">'Hyperkalemia'</a> above.)</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med 1987; 316:1429.</a></li><li><a class="nounderline abstract_t">SOLVD Investigators, Yusuf S, Pitt B, et al. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991; 325:293.</a></li><li><a class="nounderline abstract_t">Comparative effects of therapy with captopril and digoxin in patients with mild to moderate heart failure. The Captopril-Digoxin Multicenter Research Group. JAMA 1988; 259:539.</a></li><li><a class="nounderline abstract_t">SOLVD Investigators, Yusuf S, Pitt B, et al. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med 1992; 327:685.</a></li><li><a class="nounderline abstract_t">Pfeffer MA, Braunwald E, Moyé LA, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. N Engl J Med 1992; 327:669.</a></li><li><a class="nounderline abstract_t">Oster JR, Materson BJ. Renal and electrolyte complications of congestive heart failure and effects of therapy with angiotensin-converting enzyme inhibitors. Arch Intern Med 1992; 152:704.</a></li><li><a class="nounderline abstract_t">Packer M, Lee WH, Medina N, et al. Functional renal insufficiency during long-term therapy with captopril and enalapril in severe chronic heart failure. Ann Intern Med 1987; 106:346.</a></li><li><a class="nounderline abstract_t">Ljungman S, Kjekshus J, Swedberg K. Renal function in severe congestive heart failure during treatment with enalapril (the Cooperative North Scandinavian Enalapril Survival Study [CONSENSUS] Trial). Am J Cardiol 1992; 70:479.</a></li><li><a class="nounderline abstract_t">Packer M, Lee WH, Kessler PD, et al. Identification of hyponatremia as a risk factor for the development of functional renal insufficiency during converting enzyme inhibition in severe chronic heart failure. J Am Coll Cardiol 1987; 10:837.</a></li><li><a class="nounderline abstract_t">MacDowall P, Kalra PA, O'Donoghue DJ, et al. Risk of morbidity from renovascular disease in elderly patients with congestive cardiac failure. Lancet 1998; 352:13.</a></li><li><a class="nounderline abstract_t">Dzau VJ, Colucci WS, Hollenberg NK, Williams GH. Relation of the renin-angiotensin-aldosterone system to clinical state in congestive heart failure. Circulation 1981; 63:645.</a></li><li><a class="nounderline abstract_t">Schunkert H, Ingelfinger JR, Hirsch AT, et al. Evidence for tissue-specific activation of renal angiotensinogen mRNA expression in chronic stable experimental heart failure. J Clin Invest 1992; 90:1523.</a></li><li><a class="nounderline abstract_t">Packer M, Lee WH, Yushak M, Medina N. Comparison of captopril and enalapril in patients with severe chronic heart failure. N Engl J Med 1986; 315:847.</a></li><li><a class="nounderline abstract_t">Giles TD, Katz R, Sullivan JM, et al. Short- and long-acting angiotensin-converting enzyme inhibitors: a randomized trial of lisinopril versus captopril in the treatment of congestive heart failure. The Multicenter Lisinopril-Captopril Congestive Heart Failure Study Group. J Am Coll Cardiol 1989; 13:1240.</a></li><li><a class="nounderline abstract_t">Hirsch AT, Talsness CE, Smith AD, et al. Differential effects of captopril and enalapril on tissue renin-angiotensin systems in experimental heart failure. Circulation 1992; 86:1566.</a></li><li><a class="nounderline abstract_t">Ahmed A, Fonarow GC, Zhang Y, et al. Renin-angiotensin inhibition in systolic heart failure and chronic kidney disease. Am J Med 2012; 125:399.</a></li><li><a class="nounderline abstract_t">Textor SC, Bravo EL, Fouad FM, Tarazi RC. Hyperkalemia in azotemic patients during angiotensin-converting enzyme inhibition and aldosterone reduction with captopril. Am J Med 1982; 73:719.</a></li><li><a class="nounderline abstract_t">Motwani JG, Fenwick MK, Morton JJ, Struthers AD. Furosemide-induced natriuresis is augmented by ultra-low-dose captopril but not by standard doses of captopril in chronic heart failure. Circulation 1992; 86:439.</a></li><li><a class="nounderline abstract_t">McLay JS, McMurray JJ, Bridges AB, et al. Acute effects of captopril on the renal actions of furosemide in patients with chronic heart failure. Am Heart J 1993; 126:879.</a></li><li><a class="nounderline abstract_t">Good JM, Brady AJ, Noormohamed FH, et al. Effect of intense angiotensin II suppression on the diuretic response to furosemide during chronic ACE inhibition. Circulation 1994; 90:220.</a></li><li><a class="nounderline abstract_t">Dzau VJ, Colucci WS, Williams GH, et al. Sustained effectiveness of converting-enzyme inhibition in patients with severe congestive heart failure. N Engl J Med 1980; 302:1373.</a></li><li><a class="nounderline abstract_t">Leier CV. Regional blood flow responses to vasodilators and inotropes in congestive heart failure. Am J Cardiol 1988; 62:86E.</a></li></ol></div><div id="topicVersionRevision">Topic 2365 Version 15.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2883575" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2057034" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2447297" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Comparative effects of therapy with captopril and digoxin in patients with mild to moderate heart failure. The Captopril-Digoxin Multicenter Research Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1463530" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1386652" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1558426" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Renal and electrolyte complications of congestive heart failure and effects of therapy with angiotensin-converting enzyme inhibitors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3028221" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Functional renal insufficiency during long-term therapy with captopril and enalapril in severe chronic heart failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1642186" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Renal function in severe congestive heart failure during treatment with enalapril (the Cooperative North Scandinavian Enalapril Survival Study [CONSENSUS] Trial).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2821091" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Identification of hyponatremia as a risk factor for the development of functional renal insufficiency during converting enzyme inhibition in severe chronic heart failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9800739" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Risk of morbidity from renovascular disease in elderly patients with congestive cardiac failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7006851" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Relation of the renin-angiotensin-aldosterone system to clinical state in congestive heart failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1401084" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Evidence for tissue-specific activation of renal angiotensinogen mRNA expression in chronic stable experimental heart failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3018566" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Comparison of captopril and enalapril in patients with severe chronic heart failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2539403" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Short- and long-acting angiotensin-converting enzyme inhibitors: a randomized trial of lisinopril versus captopril in the treatment of congestive heart failure. The Multicenter Lisinopril-Captopril Congestive Heart Failure Study Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1330361" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Differential effects of captopril and enalapril on tissue renin-angiotensin systems in experimental heart failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22321760" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Renin-angiotensin inhibition in systolic heart failure and chronic kidney disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6291388" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Hyperkalemia in azotemic patients during angiotensin-converting enzyme inhibition and aldosterone reduction with captopril.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1638713" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Furosemide-induced natriuresis is augmented by ultra-low-dose captopril but not by standard doses of captopril in chronic heart failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8213445" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Acute effects of captopril on the renal actions of furosemide in patients with chronic heart failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8026000" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Effect of intense angiotensin II suppression on the diuretic response to furosemide during chronic ACE inhibition.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6246425" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Sustained effectiveness of converting-enzyme inhibition in patients with severe congestive heart failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2901217" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Regional blood flow responses to vasodilators and inotropes in congestive heart failure.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
